Bayer AG's stock price currently stands at $36.84, reflecting a decrease of $1.54 (-4.01%) from the previous close of $38.38. The trading volume has surged by 68.82% to $2.37 million. This decline in price is notable, indicating a bearish sentiment driven by increased selling pressure.
Bayer AG has experienced a three-day streak of declining prices. The stock price has dropped by $3.4 (-8.45%) from $40.24 to the current level of $36.84. This streak underscores the recent downward trend in the company's stock performance.
In the latest quarterly earnings report released on Tuesday, March 3rd, Bayer AG reported an earnings per share of 0.623, surpassing the consensus estimate of 0.3892. This positive earnings surprise may have implications for investor confidence and future stock performance.
Bayer AG offers a forward dividend yield of 1.19% and a dividend per share of 11 cents TTM. These dividends reflect the company's commitment to rewarding shareholders and maintaining financial stability.
Key financial ratios for Bayer AG include a gross profit margin of 60.65%, operating profit margin of 14.88%, and return on equity of -14.48%. These metrics provide insights into the company's financial health and operational efficiency, highlighting areas for potential improvement.
This real-time financial report offers a snapshot of Bayer AG's current performance and financial indicators, providing investors with valuable insights into the company's position in the market.
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.